Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: Histological diagnostic criteria and scoring systems

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 6, 2010, Pages 643-650

  Tiniakos, Dina G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Diagnosis; Histopathology; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Scoring

Indexed keywords

CHRONIC LIVER DISEASE; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; FATTY LIVER; FIBROSIS; HISTOPATHOLOGY; HUMAN; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SCORING SYSTEM;

ADULT; CHILD; DIAGNOSIS, DIFFERENTIAL; FATTY LIVER; FATTY LIVER, ALCOHOLIC; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; SEVERITY OF ILLNESS INDEX;

EID: 77951904416     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32832ca0cb     Document Type: Review

References (61)

1. Neuschwander-Tetri BA. Fatty liver and the metabolic syndrome. Curr Opin Gastroenterol 2007; 23: 193-198.
2. Roberts EA. Nonalcoholic steatohepatitis in children. Clin Liver Dis 2007; 11: 155-172.
3. Dunn W, Schwimmer JB. The obesity epidemic and nonalcoholic fatty liver disease in children. Curr Gastroenterol Rep 2008; 10: 67-72.
4. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923.
5. Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin N Am 2007; 91: 1125-1149.
6. Younossi ZM. Current management of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2008; 28: 2-12.
7. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43:S99-S112.
8. Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis 2007; 11: 191-207.
9. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.
10. Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6:34.
11. Wieckowska A, McCullough AJ, Feldstein A. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46: 582-589.
12. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis panel and exploring simple markers. Hepatology 2008; 47: 455-460.
13. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44: 27-33.
14. Baranova A, Younossi ZM. The future is around the corner: noninvasive diagnosis of progressive nonalcoholic steatohepatitis. Hepatology 2008; 47: 373-375.
15. Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008; 18: 1430-1437.
16. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-1123.
17. Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6:6.
18. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell CG, et al. The NAFLD Fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854.
19. Nobili V, Vizzutti F, Arena U, Abraldes JG, Marra F, Pietrobattista A, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008; 48: 442-448.
20. Yoneda M, Yoneda M, Mawatari H, Fujita K, Endo H, Iida H, et al. Nonivasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Dis Sci 2008; 40: 371-378.
21. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-847.
22. Brunt EM, Tiniakos DG. Alcoholic and non-alcoholic fatty liver disease. In: Odze RD, Goldblum JR, Crawford JM, editors. Pathology of the GI tract, liver, biliary tract and pancreas. Philadelphia: Saunders; 2009. pp. 1087-1114.
23. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362.
24. Gaidos J, Hillner BE, Sanyal AJ. A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis. Liver Int 2008; 28: 650-658.
25. Yeh M, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 2007; 128: 837-847.
26. Bondini S, Kleiner DE, Goodman Z, Gramlich T, Younossi ZM. Pathologic assessment of nonalcoholic fatty liver disease. Clin Liver Dis 2007; 11: 17-23. (Pubitemid 46829967)
27. Brunt EM, Tiniakos DG. Pathological features of NASH. Front Biosci 2005; 10: 1475-1484.
28. Brunt EM. NASH: pathologic features and differential diagnosis. Semin Diagn Pathol 2005; 22: 330-338.
29. Chalasani N, Wilson L, Kleiner DE, Cummings OW, Brunt EM, Unalp A, et al. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol 2008; 48: 829-834.
30. Hubscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology 2006; 49: 450-465.
31. Lackner C, Gogg-Kamerer J, Zatlukal K, Stumptner C, Brunt EM, Denk H. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol 2008; 48: 821-828.
32. Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, Neuschwander-Tetri BA. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD) : a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009; 49: 809-820.
33. Zatloukal K, Stumptner C, Fuchsbichler A, Fickert P, Lackner C, Trauner M, et al. The keratin cytoskeleton in liver diseases. J Pathol 2004; 204: 367-376.
34. Zatloukal K, French SW, Stumptner C, Strnad P, Harada M, Toivola DM, et al. From Mallory to Mallory-Denk bodies: what, how and why? Exp Cell Res 2007; 313: 2033-2049.
35. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192.
36. Caldwell SH, Chang CY, Nakamoto RK, Krugner-Higby L. Mitochondria in nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 595-617.
37. Pinto HC, Baptista A, Camilo ME, Valente A, Saragoça A, de Moura MC. Nonalcoholic steatohepatitis clinicopathologic comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996; 41: 172-179.
38. Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004; 39: 179-187. (Pubitemid 38461480)
39. Richardson MM, Johnsson JR, Powell EE. Progessive fibrosis in NASH-altered regeneration and the ductular reaction. Gastroenterology 2007; 133: 80-90.
40. Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005; 42: 641-649.
41. Nobili V, Marcellini M, Devito R, Ciampalini P, Piemonte F, Comparcola D, et al. NAFLD in children: a prospective clinical-pathological study and effect of life-style advice. Hepatology 2006; 44: 458-465.
42. Roberts EA, Yap J. Nonalcoholic Fatty Liver Disease (NAFLD) : approach in the adolescent patient. Curr Treat Options Gastroenterol 2006; 9: 423-431.
43. Brunt EM, Tiniakos DG. Pathology of steatohepatitis. Best Pract Res Clin Gastroenterol 2002; 16: 691-707.
44. Yip WW, Burt AD. Alcoholic liver disease. Semin Diagn Pathol 2006; 23: 149-160.
45. Sanderson SO, Smyrk TC. The use of protein tyrosine phosphatase 1B and insulin receptor immunostains to differentiate nonalcoholic from alcoholic steatohepatitis in liver biopsy specimens. Am J Clin Pathol 2005; 123: 503-509.
46. Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007; 45: 80-87.
47. Brunt EM, Ramrakhiani S, Cordes BG, Neuschwander-Tetri BA, Janney CG, Bacon BR, et al. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 2003; 16: 49-56.
48. Bedossa P, Moukari R, Chelbi E, Asselah T, Paradis V, Vidaud M, et al. Evidence for a role of NASH in Hepatitis C: a prospective study. Hepatology 2008; 46: 380-387.
49. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
50. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
51. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
52. Younossi ZM, Gramlich T, Liu YC, Matteoni C, Petrelli M, Goldblum J, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998; 11: 560-565.
53. Fukusato T, Fukushima J, Shiga J, Takahashi Y, Nakano T, Maeyama S, et al. Interobserver variation in the histopathological assessment of non-alcoholic steatohepatitis. Hepatol Res 2005; 33: 122-127.
54. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906.
55. Arun J, Jhala N, Lazenby AJ, Clements R, Abrams GA. Influence of liver biopsy heterogeneity and diagnosis of nonalcoholic steatohepatitis in subjects undergoing gastric bypass. Obes Surg 2007; 17: 155-161.
56. Janiec DJ, Jacobson ER, Freeth A, Spaulding L, Blaszyk H. Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies. Obes Surg 2005; 15: 497-501.
57. Merriman RB, Ferrell LD, Patti MG, Weston SR, Pabst MS, Aouizerat BE, et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006; 44: 874-880.
58. Larson SP, Bowers SP, Palekar NA, Ward JA, Pulcini JP, Harrison SA. Histopathologic variability between the right and left lobes of the liver in morbidly obese patients undergoing Roux-en-Y bypass. Clin Gastroenterol Hepatol 2007; 5: 1329-1332.
59. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis. J Hepatol 2003; 39: 239-244.
60. Goldstein NS, Hastah F, Galan MV, Gordon SC. Fibrosis heterogeneity in nonalcoholic steatohepatitis and hepatitis C virus needle core biopsy specimens. Am J Clin Pathol 2005; 123: 382-387.
61. Brunt EM. Do you see what I see? The role of quality histopathology in scientific study. Hepatology 2008; 47: 771-774.